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tions 7.2(±4.1); compliance score 4.8(±0.6); symptoms
6.2(±4.4); PCS-8 59.2(±7.9); MCS-8 51.2(±8.1); and VAS
82.4(±16.0). The mean WPS was 4.6(±0.5); mean
employment duration of 14.6(±12.3) years and 2.5%
reporting job dissatisfaction. Of the 3 models tested, that
with the highest explanatory ability (r-square = 0.36)
included number of symptoms, age, perceived cardiac
severity, and PCS-8, with more symptoms, higher per-
ceived severity, higher age, and lower PCS-8 scores 
associated with lower perceived work performance.
CONCLUSIONS: Currently employed ACS patients
report a high level of work performance. Symptomology,
perceived disease severity, age, and physical function
appear to be associated with work performance.
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OBJECTIVE: To model the predictive relationships of
self-reported patient-speciﬁc, independent predictor vari-
ables on dependent health-related quality of life measures
(HRQL) in an acute coronary syndrome (ACS) popula-
tion. METHODS: All ACS patients discharged from a
university afﬁliated hospital during a 3-year period were
mailed a questionnaire that included two short general
HRQL measures, the SF-8 and EQ-5D. Independent vari-
ables included cardiac functional status [Duke Activity
Status Index (DASI)], symptom count (Symptom Distress
Checklist), comorbidity index (Charlson self-adminis-
tered), patient-perceived cardiac disease severity, medica-
tion count, compliance score, patient demographics, and
ACS type [unstable angina (UA) or myocardial infarction
(MI)]. Three separate stepwise-elimination (p < 0.05)
linear regression models determined the combined pre-
dictive ability of independent variables on the PCS-8, the
MCS-8, and the EQ-5D General Health Visual Analog
Scale (VAS). RESULTS: To date, 414 of 1230 patients
(34%) have responded. The mean (±s.d.) age was
65.7(±11.3) years; 67.7% male; 94.0% Caucasian;
62.1% history of MI; and 22.9% reported severe or
worse cardiac disease severity. Respondents reported 
the following mean (±s.d.) responses: DASI 20.5(±8.1);
comorbidity index 2.5(±1.9); number of medications
8.4(±4.6); compliance score 4.8(±0.5); number of symp-
toms 7.8(±4.9); PCS-8 53.7(±10.5); MCS-8 49.5(±9.5);
and VAS 73.6(±20.5). The ﬁnal PCS model had an r-
square of 0.51 and contained the comorbidity index,
number of symptoms, age, gender, perceived cardiac
severity, household income, and type of ASC. The ﬁnal
MCS-8 model had an r-square of 0.36 and contained
number of symptoms, perceived cardiac severity, and
education level. The ﬁnal VAS model had an r-square of
0.49 and contained comorbidity index, number of symp-
toms, perceived cardiac severity, and household income
level. CONCLUSIONS: Patient self-reported measures 
of disease, cardiac functional status, symptomology, and
medication utilization formed highly predictive models 
of HRQL. Greater numbers of reported symptoms and
higher patient-perceived cardiac severity were associated
with lower HRQL in all three models.
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OBJECTIVE: The ﬁve statins currently available in the
US (atorvastatin [A], pravastatin [P], simvastatin [S], ﬂu-
vastatin [F] and lovastatin [L]) differ in terms of their 
abilities to lower LDL-C, the need to adjust dosing for
decreased renal function, potential for drug-drug interac-
tions, cost, recommended hepatic function monitoring
schedule, and level of proven effectiveness. The implica-
tions of these differences on the clinical use of statins have
been largely unexplored. The purpose of this study was
to examine the effects of these intra-class differences 
on clinical decision making using multicriteria decision
analysis. METHODS: A multicriteria decision analysis
using the Analytic Hierarchy Process (AHP) was per-
formed from the practitioner’s perspective. The goal was
deﬁned as “Choose the best statin”. Decision criteria were
based on the differences mentioned above. Costs were
included in the analysis both as internet drug store prices
(scenario 1) and in terms of patient co-pays for 3 current
three-tiered managed care formularies in Rochester, NY
(scenarios 2,3, & 4). Data comparing the statins’ perfor-
mance on the other criteria were obtained from the liter-
ature. RESULTS: Statin priority scores, which measure
the relative rankings of the alternatives’ abilities to meet
the all decision criteria (higher scores are better), for the
4 scenarios are: Scenario 1: L = 0.214, F = 0.209, P =
0.200, S = 0.190, A = 0.187; Scenario 2: P = 0.209, L =
0.208, S = 0.205, F = 0.192, A = 0.188; Scenario 3: 
P = 0.213, L = 0.208, S = 0.200, A = 0.192, F = 0.187;
Scenario 4: P = 0.209, L = 0.208, S = 0.205, A = 0.192,
F = 0.187. In addition to cost, relative priority scores in
all scenarios were affected by differences in the impor-
tance assigned to ability to lower LDL-C, ease of pre-
scribing safely, and proven effectiveness. CONCLUSION:
The relative importance of differences among statins has
a signiﬁcant impact on optimal clinical use of these drugs.
These results suggest that practitioners should be aware
of these differences and incorporate them in clinical deci-
sions regarding statin prescriptions.
